Table 1.
Elimination kinetics and group characteristics
| Group | Age year |
Gender % female |
Peak ALT IU/L |
Peak serum APAP-CYS μM |
Time until peak serum APAP-CYS hr |
Hepatic encephalo pathy # (%) |
Ingestion type % acute |
Died # (%) |
Half-life*
h |
|---|---|---|---|---|---|---|---|---|---|
| Normal N = 28 |
37 ± 3 | 46 | 2540 ± 607 | 7.6 ± 1.11 | 31 ± 4 | 5 (18) | 57 | 0 | 26.8 ± 1.1 |
| Renal failure N = 15 |
39 ± 5 | 87 | 2842 ± 898 | 8.76 ± 3.48 | 32 ± 6 | 5 (33) | 33 | 2 (13) | 41.3 ± 2.2 |
Half-life represents serum APAP-CYS terminal elimination half-life. Data for age, peak ALT, peak serum APAP-CYS, time until peak serum APAP-CYS, and half-life are presented as mean ± SEM.
* p < 0.001 (terminal elimination half-life differed between groups)